Free Whitepaper: Brexit and Biotech
In 2019, the United Kingdom is set to leave the European Union. Since many companies performing biotech clinical studies in the EU rely on third-party vendors and external consultants based in the UK, Brexit will have a dramatic effect on the testing ecosystem in Europe.
In our free whitepaper, Brexit and Biotech: Clinical Trial Solutions to Overcome the Uncertainty of Changing Regulations, we provide history and context for the UK’s departure. We also look more carefully at Brexit’s impact, including:
- A possible shortage of Qualified Persons (QPs) in the EU, since so many of the current QPs are based in the UK
- How regulatory and tax changes may affect the biotechnology clinical supply chain
The time to prepare for Brexit is now. Find out what Brexit means to your current and future clinical trials, and what you need to do to get ready.